CEO
Connor Wander, PhD, is an interdisciplinary scientist with biotech industry drug discovery experience and a passion for advancing research and scientific transparency. Connor performed his graduate training in the Pharmacology Department at UNC Chapel Hill. As a co-mentored student between the Cohen and Song Labs at UNC, Connor studied glial biology, waster clearance mechanisms, adult neurogenesis, and inhibitory neural networks in Alzheimer disease. His other scientific interests include the interactions between the environment, genetics, and nutrition in neurodegenerative diseases. Connor is currently a Scientific Consultant at Eva Garland Consulting, specializing in securing non-dilutive funding for entrepreneurs with innovative research and development programs.
Outside of the lab, Connor enjoys hobbies such as graphic design, balcony gardening, gaming, Brazilian Jiu Jitsu, paintball and caring for his bearded dragons.
Education
PhD in Pharmacology
UNC Chapel Hill 2021
B.S. In Biology and Biochemistry — Chemistry Minor
Virginia Tech 2014
Connor Wander’s Publications
- Corpora amylacea negatively correlate with hippocampal tau pathology in Alzheimer's disease
- Compensatory remodeling of a septo-hippocampal GABAergic network in the triple transgenic Alzheimer's mouse model
- Corpora amylacea are associated with tau burden and cognitive status in Alzheimer's disease
- The neurogenic niche in Alzheimer's disease
- Neuropeptides Modulate Local Astrocytes to Regulate Adult Hippocampal Neural Stem Cells
- The Accumulation of Tau-Immunoreactive Hippocampal Granules and Corpora Amylacea Implicates Reactive Glia in Tau Pathogenesis during Aging
- A unique tau conformation generated by an acetylation-mimic substitution modulates P301S-dependent tau pathology and hyperphosphorylation
- Acetylation-induced TDP-43 pathology is suppressed by an HSF1-dependent chaperone program
- A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy
Gallery
